XML 101 R81.htm IDEA: XBRL DOCUMENT
v3.22.2.2

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Private Warrants (Details) |  | 12 Months Ended |
--- | --- | --- | ---
Aug. 24, 2020 USD ($) $ / shares shares | Jun. 30, 2020 USD ($) $ / shares | Jun. 30, 2019 USD ($) $ / shares | Mar. 14, 2019 USD ($) $ / shares
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Private Warrants, Non-Current | $ |  | $ 1,686,643 |  |
Payments For Redemption Of Warrants | $ | $ 915,796 |  |  |
Exchange of warrants |  |  |  |
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Number of outstanding warrants exchanged | shares | 24,200,000 |  |  |
Number Of Shares Issued Upon Exchange Of Each Warrant | shares | 0.12 |  |  |
Cash Consideration For Exchange Of Each Warrant | $ / shares | $ 0.45 |  |  |
Number Of Warrants Validly Tendered But Not Properly Withdrawn | shares | 21,938,774 |  |  |
Aggregate Cash Consideration For Exchange Of Warrants | $ | $ 115,062 |  |  |
Number Of Warrants Redeemed | shares | 2,261,226 |  |  |
Warrants Redeemed, Offering Price Per Warrant | $ / shares | $ 0.405 |  |  |
Aggregate Number Of Shares Issued Upon Exchange Of Warrants | shares | 2,601,954 |  |  |
Private warrants. |  |  |  |
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Financial liabilities, at fair value | $ |  | 1,700,000 | $ 2,800,000 | $ 3,400,000
Gain recognized from change in fair value | $ | $ 6,200,000 | $ 1,200,000 | $ 600,000 |
Private warrants. | Volatility |  |  |  |
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Assumption used in estimating fair value |  |  |  | 32
Private warrants. | Share price |  |  |  |
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Assumption used in estimating fair value | $ / shares |  | 6.06 | 5.30 | 5.35
Private warrants. | Risk-free rate |  |  |  |
INFORMATION ABOUT COMPONENTS OF EQUITY |  |  |  |
Assumption used in estimating fair value |  | 0.29 | 1.7631 | 2.43

X
- Definition Amount of aggregate cash consideration paid upon exchange of outstanding warrants of the company. + References No definition available. + Details
Name: | biox_AggregateCashConsiderationForExchangeOfWarrants
Namespace Prefix: | biox_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate number of shares issued upon exchange of outstanding warrants of the company. + References No definition available. + Details
Name: | biox_AggregateNumberOfSharesIssuedUponExchangeOfWarrants
Namespace Prefix: | biox_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash consideration upon exchange of each outstanding warrant of the company. + References No definition available. + Details
Name: | biox_CashConsiderationForExchangeOfEachWarrant
Namespace Prefix: | biox_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of outstanding warrants exchanged by the company. + References No definition available. + Details
Name: | biox_NumberOfOutstandingWarrantsExchanged
Namespace Prefix: | biox_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued upon exchange of each outstanding warrant of the company. + References No definition available. + Details
Name: | biox_NumberOfSharesIssuedUponExchangeOfEachWarrant
Namespace Prefix: | biox_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants redeemed by the company. + References No definition available. + Details
Name: | biox_NumberOfWarrantsRedeemed
Namespace Prefix: | biox_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants validly tendered but not properly withdrawn prior to the expiration of the Offer. + References No definition available. + Details
Name: | biox_NumberOfWarrantsValidlyTenderedButNotProperlyWithdrawn
Namespace Prefix: | biox_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount paid by the entity to redeem warrants. + References No definition available. + Details
Name: | biox_PaymentsForRedemptionOfWarrants
Namespace Prefix: | biox_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The non-current amount of private warrants. + References No definition available. + Details
Name: | biox_PrivateWarrantsNonCurrent
Namespace Prefix: | biox_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Offer price per warrant at which the warrants are redeemed by the company. + References No definition available. + Details
Name: | biox_WarrantsRedeemedOfferingPricePerWarrant
Namespace Prefix: | biox_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2022-03-24 -Paragraph 25 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_FinancialLiabilitiesAtFairValue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The gains (losses) excluding exchange differences, recognised in profit or loss, on the fair value measurement of liabilities. [Refer: At fair value [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 13 -IssueDate 2022-03-24 -Paragraph 93 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_i&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The value of significant unobservable input used in the measurement of the fair value of liabilities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2022-03-24 -Paragraph 93 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_SignificantUnobservableInputLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=biox_ExchangeOfWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfContingentLiabilitiesAxis=biox_PrivateWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_UnobservableInputsAxis=biox_SharePriceMeasurementInputMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |